These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35248783)

  • 1. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
    Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].
    Deng S; Xu Y; An G; Sui W; Li Z; Zou D; Zhao Y; Qi J; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):501-6. PubMed ID: 26134017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
    Wang Y; Liu A; Xu T; Yin J; Chen W
    Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 6. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
    Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
    Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
    Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
    Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
    Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
    Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
    Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
    [No Abstract]   [Full Text] [Related]  

  • 15. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
    Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
    Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
    Chao Y; Fan L; Gao XY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the Prognostic Value and Risk Factors of Early Relapse for Newly Diagnosed Multiple Myeloma Patients in the Era of Novel Agents].
    Li QH; Liu Y; Wang J; Wang JJ; Dong F; Yang P; Wan W; Ke XY; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):148-153. PubMed ID: 36765492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.